I
BPMC

InceptionR’s Blueprint Medicines BPMC Stock Holding History

InceptionR’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,416
Closed -$214K – 662
2025
Q1 		$214K Buy
+2,416
New +$236K 0.06% 456
2024
Q4 		– Sell
-11,642
Closed -$1.08M – 634
2024
Q3 		$1.08M Buy
+11,642
New +$1.16M 0.26% 111

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

InceptionR's BPMC Position: Q2 2025 in Review

InceptionR sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 2,416 shares — an estimated $214K sold.

InceptionR first reported a position in BPMC in Q3 2024 and held it in 2 quarters. The position peaked at $1.08M in Q3 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • InceptionR reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • InceptionR sold 2,416 Blueprint Medicines shares in Q2 2025, an estimated $214K.
  • InceptionR first reported a position in Blueprint Medicines in Q3 2024 and held it in 2 quarters.
  • InceptionR's Blueprint Medicines position peaked at $1.08M in Q3 2024.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on InceptionR's 13F filing for Q2 2025, filed 12 Aug 2025.